Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CPBIO Holding CoCAIHF 58 Peter Lynch Fair Value is $1.50 as of Aug. 31, 2026. GuruFocus rates CAIHF with a GF Score™ of 58/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 253 Drug Manufacturers companies, CPBIO Holding Co ranks better than 72.73% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, CPBIO Holding Co's PEG is 1. CPBIO Holding Co's 5-Year TTM EBITDA Growth Rate is 11.54.
CPBIO Holding Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.13. Therefore, the Peter Lynch Fair Value for today is $1.50.
As of today (2026-08-31), CPBIO Holding Co's share price is $1.0677. CPBIO Holding Co's Peter Lynch fair value is $1.50. Therefore, CPBIO Holding Co's Price to Peter Lynch Fair Value Ratio for today is 0.71.
The historical rank and industry rank for CPBIO Holding Co's Peter Lynch Fair Value or its related term are showing as below:
CAIHF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55 Med: 0.59 Max: 0.76
Current: 0.76
During the past 12 years, the highest Price to Peter Lynch Fair Value Ratio of CPBIO Holding Co was 0.76. The lowest was 0.55. And the median was 0.59.
CAIHF's Price-to-Peter-Lynch-Fair-Value is ranked better than 72.73% of 253
companies
in the Drug Manufacturers industry
Industry Median: 1.27
vs CAIHF: 0.76
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
CPBIO Holding Co (OTCPK:CAIHF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 11.54 instead of 15 in this case.
CPBIO Holding Co's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
1.0677
/
1.50
=
0.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co Peter Lynch Fair Value Related Terms
CPBIO Holding Co Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's Price-to-Peter-Lynch-Fair-Value falls into.
CPBIO Holding Co's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $0.13.
* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
CPBIO Holding Co (CAIHF) has a Peter Lynch Fair Value of $1.50 as of Aug. 31, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CPBIO Holding Co and its competitors. According to the industry distribution chart, CPBIO Holding Co ranks #69 out of 253 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is CPBIO Holding Co's Peter Lynch Fair Value too high?
CPBIO Holding Co's current Peter Lynch Fair Value is $1.50. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.27. CPBIO Holding Co's value of $1.50 is 18.1% above this industry median. Based on the distribution chart, CPBIO Holding Co ranks #69 out of 253 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CPBIO Holding Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Peter Lynch Fair Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #69 out of 253 companies for Peter Lynch Fair Value. This puts CPBIO Holding Co in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.27. CPBIO Holding Co's value of $1.50 is 18.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.27, based on 253 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CPBIO Holding Co's current Peter Lynch Fair Value of $1.50 is 18.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current Peter Lynch Fair Value is $1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (CAIHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.07 — trading 567.3% above its estimated fair value. The current Peter Lynch Fair Value is $1.50 and 18.1% above the Drug Manufacturers industry median of 1.27. CPBIO Holding Co's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For CPBIO Holding Co (CAIHF), the current Peter Lynch Fair Value is $1.50 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (CAIHF) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of $1.07 is trading 567.3% above its estimated GF Value™ of $0.16.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for CAIHF:
Peter Lynch Fair Value: $1.50
GF Value™: $0.16 vs. price of $1.07 (567.3% above fair value)
Industry Position: 18.1% above the Drug Manufacturers median (#69 of 253)
No single metric tells the full story. See the CAIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
58GF Score
Get the complete analysis for CAIHF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAIHF has been successfully added to your 
